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Soft-tissue sarcomas (STSs) are classified into various histopatho-
logical types such as malignant fibrous histiocytoma (MFH),
liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma
and malignant schwannoma (Enzinger et al, 1969; Enjoji et al,
1984). However, possible genetic differences among these types,
for example what molecular alterations occur commonly or corre-
spond particularly to each tumour type, have not been established.
Mutations of the p53 gene have been detected in STSs (Masuda
et al, 1987; Toguchida et al, 1992) as well as in solid tumours from
colon, breast and lung. The reported frequencies of p53 mutations
in STSs vary: 10–36% in MFH, 11–23% in liposarcoma, 14–38%
in leiomyosarcoma (Stratton et al, 1990; Toguchida et al, 1992;
Andreassen et al, 1993; Leach et al, 1993; Castresana et al, 1994,
1995; Latres et al, 1994; Taubert et al, 1995, 1996; Würl et al,
1996; Schneider-Stock et al, 1997) and 33% in malignant schwan-
noma (Schneider-Stock et al, 1997). Stratton et al (1990), Felix
et al (1992) and Würl et al (1996) reported that one-third of the
rhabdomyosarcomas they examined had p53 mutations, but only a
few mutations of that gene have been found in fibrosarcomas
(Latres et al, 1994; Taubert et al, 1996). Mutation of p53 is rare in
synovial sarcomas (Andreassen et al, 1993; Taubert et al, 1996).
Hence the role of p53 mutations in STSs is still unclear.
Furthermore, in some tumours carrying wild-type p53, functional
inactivation of p53 can also occur through with overexpressed
mdm2 which inhibit p53 function by concealing its transcriptional
activation domain or destabilizing endogenous p53 protein (Haupt
et al, 1997; Kubbutat et al, 1997). It has been reported that the
mdm2 gene amplification was observed in more than 30% of
human sarcomas (Oliner et al, 1992; Leach et al, 1993; Cordon-
Cardo et al, 1994).
The wide variety of biological functions of p53 result from its
transcriptional activation of downstream genes such as
p21/WAF1, GADD45, GML and BAX (Kastan et al, 1992;
Vogelstein and Kinzler, 1992; Wu et al, 1993; Okamoto and
Beach, 1994; Buckbinder et al, 1995; Miyashita and Reed 1995;
Furuhata et al, 1996; Morris et al, 1996). When p53 functions are
suppressed by p53 mutation or overexpression of mdm2, expres-
sion of these and unidentified downstream genes, including genes
that encode tissue-specific factors as well as common components,
are likely to be down- or up-regulated, and their dysfunctional
products could be expected to contribute to tumour formation
and/or progression. Although a number of p53-target genes have
already been isolated, most of them have not been examined
intensively for alterations in human primary cancers.
Recently we isolated a human p53-inducible gene, P2XM,
encoding a member of the P2X-receptor family of adenosine 5¢
triphosphate (ATP) gated ion channels (Urano et al, 1997). Its
amino acid sequence contains two predicted transmembrane
domains (M1 and M2) and a segment resembling the H5 region of
voltage-gated K+ channels that are expressed predominantly in
skeletal muscle. In a previous report we described the complete
loss of expression of P2XM, or an altered expression pattern in
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domains, in cell lines derived from rhabdomyosarcomas or
osteosarcomas (Urano et al, 1997). Those findings suggested that
loss of normal function of the p53-P2XM signal-transduction
pathway might be associated with tumorigenesis in bone or soft
tissue.
To address this question, we examined expression of P2XM, as
well as the mutation status of p53 and overexpression of mdm2,
in 56 primary malignant and benign soft-tissue tumours.
MATERIALS AND METHODS
Patients and tissues
We obtained materials from 56 patients (29 males and 27 females)
who underwent definitive surgical treatment for soft-tissue
tumours at Osaka University Medical School Hospital or at the
Osaka Medical Center for Cancer and Cardiovascular Diseases,
Osaka, Japan. Of the 47 tumours that were malignant, 15 were
diagnosed histopathologically as malignant fibrous histiocytomas
(MFHs), nine as liposarcomas, seven as synovial sarcomas, six as
malignant schwannomas, three as leiomyosarcomas, two as rhab-
domyosarcomas, two as alveolar soft-part sarcomas and three as
‘other’ or unclassified sarcomas. The ages of the patients at first
diagnosis ranged from 6 to 81 years (mean 47.7 years). We also
selected nine benign soft-tissue tumours for study, including three
lipomas, two desmoid tumours, two schwannomas, one heman-
gioma and one fibroma.
RT-PCR of P2XM and mdm2 transcripts
Samples of total RNA extracted from tumour tissues were
reversely transcribed to single-stranded cDNAs using oligo(dT)15
primer and superscript II (GibcoBRL, Life Technologies,
Rockville, MD, USA). Semiquantitative Polymerase chain reac-
tion (PCR) experiments were performed with cDNA samples
whose concentrations were equalized with 20 cycles of PCR
amplification of gluceraldehyde 3-phosphate dehydrogenase
(GAPDH). The reactions were performed using Ex Taq (TaKaRa,
Otsu, Japan), with an initial step of 94°C for 3 min followed by
20–35 cycles at 94°C for 30 s, 58°C for 30 s and 72°C for 30 s, on
the GeneAmp PCR system 9600 (Perkin Elmer-Cetus). Primer
sequences for analysing expression patterns and splice-forms of
P2XM were E1F (5¢-GGCTCCCCAGGGGCTACGACA-3¢) and
261R (5¢-CCTTGATCTGAGTGACGGAA-3¢) for the AL1
region, and 811F (5¢-TGCTGGCCTCACTACTCCTT-3¢) and
1259R (5¢-GGTTGGCAAGTGGGTGTCAG-3¢) for the AL2 and
AL3 regions together. For analysing the coding region of mdm2
transcripts, PCR was performed by 35 cycles at 94°C for 30 s,
55°C for 30 s and 72°C for 3 min using a sense primer (5¢-GATG-
GTGCTGTAACCACCTC-3¢) and an antisense primer (5¢-CTAC-
TAGAAGTTGATGGCTGAG-3¢) and 665-bp PCR products were
resolved by electrophoresis in 2% agarose gels.
PCR-SSCP screening for p53 mutations
A total of 100 ng of each tumour DNA were amplified by the PCR
using Ex Taq and 5 pM of each primer in 35 cycles under the
cycling conditions described for the reverse transcription-PCR
(RT-PCR) of P2XM. The primer sequences designed to amplify
each exon from 5 to 8 and parts of adjacent introns were E5F (5¢-
CTTGTGCCCTGACTTTCAAC-3¢) and E5R (5¢-TCTCCAGCC-
CCAGCTGCTC-3¢) for exon 5; E6F (5¢-TGATTCCTCACT-
GATTGCTCT-3¢) and E6R (5¢-CCAGAGACCCCAGTTGCA-
AAC-3¢) for exon 6; E7F (5¢-TCTTGGGCCTGTGTTATCTC-3¢)
and E7R (5¢-TGCAGGGTGGCAAGTGGCTCC-3¢) for exon 7;
and E8F (5¢-GCTTCTCTTTTCCTATCCTGA-3¢) and E8R (5¢-
ACCGCTTCTTGTCCTGCTTGC-3¢) for exon 8. We performed
non-radioactive single strand conformation polymorphism (SSCP)
analysis using a FMBIOII Multiview fluorescent image analyser
(TaKaRa, Otsu, Japan). A 2.5-ml aliquot of PCR product from each
sample was mixed with SSCP-loading buffer that contained 95%
formamide, 10 mM EDTA, 0.25% bromophenol blue and
xylenecyanol, boiled for 5 min and placed on ice. Twenty
microlitres of each mixture was electrophoresed with 0.5% TBE
buffer for 12 h in a 5% polyacrylamide gel containing 10% glyc-
erol, at a continuous 500 volts, in a chromatography chamber
maintained at 4°C. After electrophoresis, the gels were stained for
5 min with SYBR GREEN II (FMC Bioproducts, Rockland, ME,
USA) diluted 1/100 000 with 0.5 ´ TBE, and visualized by scan-
ning with the FMBIOII imager. Aberrant bands were extracted
from the gels into 500 ml of TE and boiled for 30 min; 1 ml of this
solution was used for the second PCR amplification.
Cloning and sequencing of extracted DNA fragments
The second PCR for each extracted DNA fragment was performed
using the same primers and conditions as in the first PCR.
Amplified products were electrophoresed in 2% agarose gels; each
band was excised and its DNA extracted using the Qiagen (Santa
Clarita, CA, USA) DNA extraction kit. The DNA fragments were
blunt-ended and cloned into the EcoRV site of pBluescript II
(Stratagene, La Jolla, CA, USA). Five clones of each fragment
were sequenced to avoid errors due to mis-incorporation of Taq
polymerase or contamination by PCR products amplified from
retained or coexistent normal alleles. Sequencing was performed in
an ABI model 373 auto-sequencer (Perkin Elmer-Cetus) by the
dideoxy chain-termination method, using the AmpliTaq FS
cycle-sequencing kit (Applied Biosystems, Foster City, CA, USA).
RESULTS
Analysis of P2XM expression
In our previous study of P2XM expression in cell lines derived
from soft-tissue or bone tumours we noted, in addition to the full-
size transcript, three splicing variants which lacked parts of, or
entire, exons (Figure 1). The first alternatively spliced form, AL1,
lacked a 78-bp portion of exon 1 which would encode part of the
M1 transmembrane domain. The second variant, AL2, deleted
exon 10 (66-bp); exons 10 and 11 (144-bp) were both eliminated
in the third splicing variant, AL3. As the M2 transmembrane
domain would be encoded by exons 10 and 11, the proteins trans-
lated from AL2 and AL3 would have no intact M2 moiety. In the
present study, we performed RT-PCR using primers to amplify
separate regions (N1 and N2) spanning the M1 or M2 transmem-
brane domains respectively, in normal muscle and in a large panel
of primary soft-tissue tumours. In normal skeletal muscle, the 155-
bp AL1 transcript is expressed at a level significantly lower than
that of the 233-bp normal (N1) transcript (Figure 2). Similarly,
AL2 (402-bp) and AL3 (324-bp) transcripts were expressed in
much lower quantities than the 468-bp normal transcript of this
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(poly-A) RNA derived from multiple tissues detected only the full-
sized P2XM transcript in skeletal muscle (data not shown); this
result supported the view that the alternatively spliced forms are
normally expressed at very low abundance. We analysed expres-
sion of P2XM in 47 STSs and nine benign tumours, and judged
that expression was lost (LOE) when neither the normal transcript
nor any splicing variant was detectable on agarose gel elec-
trophoresis after 35 cycles of PCR amplification in the regions
corresponding to M1 and M2 (for example, T15 and T24 in Figure
2). When any splicing variant (AL1, 2, or 3) was expressed more
abundantly than the normal transcript (e.g. T21, T6, T40, and T7 in
Figure 2), we scored such tumours as aberrant transcript-dominant
(ATD). As summarized in Table 1, 34 (72%) of the 47 sarcomas
we examined revealed aberrant expression patterns of P2XM; 12
cases showed the LOE pattern and 22 had the ATD pattern. Even
the majority of benign tumours revealed aberrant expression of
P2XM; among the nine such tumors examined, four showed the
LOE pattern and three the ATD pattern. We found no correlation
between histopathological type and the pattern of P2XM expres-
sion. None of the tumours examined produced abundant AL3, but
abundant expression of AL1 and AL2 variants was observed in 16
(34%) and 13 (28%) of the 47 sarcomas respectively. Nine
tumours (seven malignant and two benign) revealed elevated
expression of transcripts that exhibited both AL1 and AL2 types
of variation, while 16 others expressed transcripts involving
alteration of only one region.
Screening of p53 mutations
We analysed the same panel of tumours for mutations in the p53
gene, specifically in exonic and flanking intronic sequences
covering exons 5–8 where most p53 mutations tend to be clus-
tered. PCR-SSCP analysis detected nine aberrant bands in eight
tumours, including five of the MFHs, one liposarcoma, one
synovial sarcoma and one lipoma. DNA sequencing of these bands
disclosed seven different mis-sense mutations, one non-sense
mutation, and a 6-bp deletion (Table 2). The liposarcoma (T7)
contained both a mis-sense mutation and a 6-bp deletion. All nine
mutations were confirmed by repeated experiments.
Among the eight tumours carrying mutant p53 alleles, all except
one MFH (T25) had shown aberrant expression of P2XM; in five
of them, expression of splice-form(s) was elevated and in the other
two P2XM expression was lost altogether.
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Figure 1 Schematic presentation of alternatively spliced variants. N1, normal transcript of the 5¢ portion of P2XM containing M1. AL1 (alternative splicing 1)
lacks part of the transmembrane domain encoded in exon 1. Alternative splice-forms 2 (AL2) and 3 (AL3) respectively lack exon(s) 10 and 10–11 of the normal
transcript (N2) that encodes M2
SM T15 T24 T25 T21 T6 T40 T7
(233-bp)
(155-bp)
(468-bp)
(402-bp)
(324-bp)
N1
AL1
N2
AL2
AL3
GAPDH
Figure 2 RT-PCR products of regions N1 and N2 of P2XM, containing the
M1 and M2 domains respectively, in several soft-tissue tumours. SM, normal
skeletal muscle; T15, leiomyosarcoma; T24, rhabdomyosarcoma; T25 and
T21, MFHs; T6, T40 and T7, liposarcomas
SM T8 T41 T40 T30 T43 T48
(665-bp) mdm2
GAPDH
Figure 3 RT-PCR products corresponding to a part of coding region of
mdm2. In a comparision to normal skeletal muscle (SM), increased products
were demonstrated in lanes amplified from T8 and T41. SM, normal skeletal
muscle; T8, T40, T41 and T43, liposarcomas; T30 and T48, MFHsAnalysis of mdm2 overexpression
In the present study, we also performed semiquantitative RT-PCR
for analysing overexpression of mdm2 transcript. We judged that
mdm2 was overexpressed when the density of the band corre-
sponding to a part of mdm2 was increased more than five times in
a comparison to that of normal skeletal muscle by agarose gel
electrophoresis after PCR amplification (Figure 3). Over-
expression of mdm2 was observed in five sarcomas, including two
liposarcomas, one each of synovial sarcoma, ASPS and unclassi-
fied sarcoma which carried wild-type p53. Three out of five
tumours with mdm2 overexpression showed abnormal P2XM
expression pattern; two ATD and one LOE patterns. Therefore, ten
out of 13 soft-tissue tumours with either p53 mutation or mdm2
overexpression demonstrated abnormal expression of P2XM.
DISCUSSION
In the study reported here, we found that 34 (72%) of the 47 soft-
tissue sarcomas we examined exhibited altered expression of the
P2XM gene; in 12 cases expression was lost and in 22 cases the
majority of the putative gene products were considered to have
lost one or both of the transmembrane domains. We found no alter-
ations in either of two alveolar softpart sarcomas, but were unable
to demonstrate any significant correlation between P2XM alter-
ations and histological types. In three-fourths of the tumours with
aberrant splicing, transcripts containing variants of either the AL1
or AL2 type were expressed predominantly; the rest produced
transcripts that included both variations. However, none of the
tumours was found to have elevated expression of the AL3 type of
transcript previously demonstrated in the cell lines. Although the
mechanism involved in alternative splicing of the P2XM gene is
not clear, it is certain that the AL1 and/or AL2 transcripts were
selectively up-regulated at the transcriptional level in the tumour
cells studied here. It is notable that aberrant patterns were also
seen in benign tumours such as lipoma, desmoid tumour and
schwannoma, and at a similar frequency. These results suggested
that the loss of function of P2XM is related to tumorigenesis in
various types of soft-tissue tumours, both malignant and benign.
The P2XM gene, a member of the P2X family of receptors that
open cationic channels by binding ATP, contains two transmem-
brane domains and an H5 region characteristic of voltage-gated
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Table 1 Expression pattern of P2XM and p53/mdm2 status in soft tissue tumours
Histological type Number Loss of Abundant splicing variants Total no. p53 mutation or
of cases expression AL1 AL2 AL1 and/or AL2 P2XM mdm2 overexpression
Soft tissue sarcoma
MFH 15 3 5 5 7 10 5
Liposarcoma 9 1 3 2 5 6 3
Synovial sarcoma 7 4 3 2 3 7 2
Malignant schwannoma 6 1 2 2 3 4 0
Leiomyosarcoma 3 1 1 1 2 3 0
Rhabdomyosarcoma 2 1 1 1 1 2 0
Alveolar softpart sarcoma 2 0 0 0 0 0 1
Other and unclassified 3 1 1 0 1 2 1
Total 47 12 16 13 22 34 12
Benign tumour
Lipoma 3 1 2 2 2 3 1
Desmoid tumour 2 1 0 1 1 2 0
Schwannoma 2 1 0 0 0 1 0
Other 2 1 0 0 0 1 0
Total 9 4 2 3 3 7 1
Total 56 16 18 16 25 41 13
Table 2 Mutations of p53 and mdm2 status in soft tissue sarcomas and benign soft tissue tumours
Mutations of p53
mdm2 Expression pattern of
Case Histology Exon Codon Mutation Resulting change overexpression P2XM
T7 Liposarcoma 7 239–241 6bp deletion Asn-Ser-Ser-> Thr – Abundance of AL2
7 253 ACC->GCC Thr->Ala
T8 Liposarcoma – + Abundance of AL2
T41 Liposarcoma – + Abundance of AL1
T20 Lipoma 5 169 ATG->GTG Met->Val – Abundance of AL1 and AL2
T12 Synovial sarcoma 6 194 CTT->TTT Leu->Phe – Abundance of AL1 and AL2
T13 Synovial sarcoma – + Loss of expression
T22 MFH 5 175 CGC->CAC Arg->His – Loss of expression
T25 MFH 7 241 TCC->ACC Ser->Thr – Normal
T32 MFH 6 213 CGA->TGA Stop at codon 213 – Loss of expression
T55 MFH 5 126 TAC->TTC Tyr->Phe – Abundance of AL1
T56 MFH 7 248 CGG->CAG Arg->Gln – Abundance of AL1 and AL2
T35 ASPS – + Normal
T14 Unclassified – + NormalK+ channels. Furthermore, it bears nucleotide-sequence similarity
to RP-2, a gene that is induced when thymocytes are undergoing
apoptosis (Owens et al, 1991). These observations may indicate
that the function of P2XM is associated with programmed cell
death, mediated by ATP or synaptic transmission. Considering that
p53 is a key player in the apoptosis pathway, p53-inducible P2XM
is likely to be involved in this process.
SSCP analysis and subsequent DNA sequencing disclosed p53
mutations in seven sarcomas and one benign lipoma. The
frequency of p53 mutations in our panel of tumours is close to the
average frequency generally reported in soft-tissue tumours
(10–33%) (Stratton et al, 1990; Toguchida et al, 1992; Taubert
et al, 1995, 1996; Würl et al, 1996; Schneider-Stock et al, 1997).
The pattern of P2XM expression was changed in all of the
tumours carrying p53 mutations except for one MFH (T25) with a
mis-sense mutation at codon 241. In the rest of the tumours with
wild-type p53, three sarcomas with mdm2 overexpression (T8,
T41 and T13) showed altered pattern of P2XM expression. Hence,
in a majority of tumours (31 out of 43) that had wild-type p53
without mdm2 overexpression, P2XM expression was altered,
genetic factor(s) other than p53 or mdm2 may contribute for aber-
rant P2XM expression. Our study suggests that an insufficiency of
normal P2XM, as a consequence of being down-regulated due to
p53 mutation, mdm2 overexpression or as the result of deregula-
tion of the splicing machinery, could contribute to development
and/or progression of the majority of soft-tissue tumours.
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